These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34117082)

  • 21. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
    Gansevoort RT; van Gastel MDA; Chapman AB; Blais JD; Czerwiec FS; Higashihara E; Lee J; Ouyang J; Perrone RD; Stade K; Torres VE; Devuyst O;
    Kidney Int; 2019 Jul; 96(1):159-169. PubMed ID: 30898339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
    Geurts F; Xue L; Kramers BJ; Zietse R; Gansevoort RT; Fenton RA; Meijer E; Salih M; Hoorn EJ;
    Clin J Am Soc Nephrol; 2023 Nov; 18(11):1426-1434. PubMed ID: 37574650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies.
    Chebib FT; Zhou X; Garbinsky D; Davenport E; Nunna S; Oberdhan D; Fernandes A
    Kidney Med; 2023 Jun; 5(6):100639. PubMed ID: 37250503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
    Moriyama T; Nakayama Y; Soejima M; Yokota Y; Ota K; Ito S; Kodama G; Nakamura N; Kurokawa Y; Yano J; Ueda U; Takamiya Y; Kaida Y; Hazama T; Shibata R; Koda Y; Fukami K
    Clin Exp Nephrol; 2021 Mar; 25(3):251-260. PubMed ID: 33141305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
    Gansevoort RT; Meijer E; Chapman AB; Czerwiec FS; Devuyst O; Grantham JJ; Higashihara E; Krasa HB; Ouyang J; Perrone RD; Torres VE;
    Nephrol Dial Transplant; 2016 Nov; 31(11):1887-1894. PubMed ID: 26681730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolvaptan in patients with autosomal dominant polycystic kidney disease.
    Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang J; Czerwiec FS;
    N Engl J Med; 2012 Dec; 367(25):2407-18. PubMed ID: 23121377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.
    Li X; Li W; Li Y; Dong C; Zhu P
    Nefrologia (Engl Ed); 2023; 43(6):731-741. PubMed ID: 37150675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model.
    McEwan P; Bennett Wilton H; Ong ACM; Ørskov B; Sandford R; Scolari F; Cabrera MV; Walz G; O'Reilly K; Robinson P
    BMC Nephrol; 2018 Feb; 19(1):37. PubMed ID: 29439650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.
    Bargagli M; Dhayat NA; Anderegg M; Semmo M; Huynh-Do U; Vogt B; Ferraro PM; Fuster DG
    Clin J Am Soc Nephrol; 2020 Jul; 15(7):1007-1014. PubMed ID: 32527945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
    Torres VE; Devuyst O; Chapman AB; Gansevoort RT; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Sergeyeva O;
    Am J Nephrol; 2017; 45(3):257-266. PubMed ID: 28166521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease.
    Mader G; Mladsi D; Sanon M; Purser M; Barnett CL; Oberdhan D; Watnick T; Seliger S
    BMC Nephrol; 2022 Oct; 23(1):334. PubMed ID: 36258169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
    Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Lee J; Hoke ME; Estilo A; Sergeyeva O
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):48-58. PubMed ID: 33376102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.
    Higashihara E; Horie S; Muto S; Kawano H; Tambo M; Yamaguchi T; Taguchi S; Kaname S; Yokoyama K; Yoshioka T; Furukawa T; Fukuhara H
    Am J Nephrol; 2020; 51(11):881-890. PubMed ID: 33227802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
    Chonchol M; Gitomer B; Isakova T; Cai X; Salusky I; Pereira R; Abebe K; Torres V; Steinman TI; Grantham JJ; Chapman AB; Schrier RW; Wolf M
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1461-1469. PubMed ID: 28705885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT; Torres VE
    Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
    Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Koch G; Ouyang J; McQuade RD; Blais JD; Czerwiec FS; Sergeyeva O;
    N Engl J Med; 2017 Nov; 377(20):1930-1942. PubMed ID: 29105594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effectiveness and safety of tolvaptan in autosomal dominant polycystic kidney disease.
    Cantarelli L; Gutiérrez Valencia M; Leache Alegria L; Sainz Fernandez LC; Erviti Lopez J; Gutiérrez Nicolas F; Nazco Casariego GJ
    Med Clin (Barc); 2024 Jul; 163(1):1-7. PubMed ID: 38616432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy.
    Yamazaki M; Kawano H; Miyoshi M; Kimura T; Takahashi K; Muto S; Horie S
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
    BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease.
    Iijima H; Tada T; Hashimoto M; Nishimura T; Kiriki M; Higashiura A; Iwasaki A; Honda M; Nagasawa Y; Yamakado K
    J Med Ultrason (2001); 2023 Jan; 50(1):81-87. PubMed ID: 36333536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.